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Cell Surface CD74–MIF Interactions Drive Melanoma
Survival in Response to Interferon-γ
Keiji Tanese1,2,5, Yuuri Hashimoto1,5, Zuzana Berkova3, Yuling Wang4, Felipe Samaniego3,
Jeffrey E. Lee4, Suhendan Ekmekcioglu1 and Elizabeth A. Grimm1
Melanoma is believed to be a highly immunogenic tumor and recent developments in immunotherapies are
promising. IFN-γ produced by immune cells has a crucial role in tumor immune surveillance; however, it has also
been reported to be pro-tumorigenic. In the current study, we found that IFN-γ enhances the expression of
CD74, which interacts with its ligand, macrophage migration inhibitory factor (MIF), and thereby activates the
PI3K/AKT pathway in melanoma, promoting tumor survival. IFN-γ increased phosphorylation of AKT Ser473 and
upregulated total cell surface expression of CD74 in human melanoma cell lines tested. CD74 was highly
expressed in melanoma tissues. Moreover, the expression of CD74 on tumor cells correlated with plasma IFN-γ
levels in melanoma patient samples. In our analysis of melanoma cell lines, all produced MIF constitutively.
Blockade of CD74–MIF interaction reduced AKT phosphorylation and expression of pro-tumorigenic molecules,
including IL-6, IL-8, and BCL-2. Inhibition of CD74–MIF interaction signiﬁcantly suppressed tumor growth in the
presence of IFN-γ in our xenograft mouse model. Thus, we conclude that IFN-γ promotes melanoma cell survival
by regulating CD74–MIF signaling, suggesting that targeting the CD74–MIF interaction under IFN-γ-stimulatory
conditions would be an effective therapeutic approach for melanoma.
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INTRODUCTION
Melanoma, the most aggressive skin cancer, is believed to be
a highly immunogenic tumor. Therefore, numerous immuno-
therapies such as cytokines, cancer vaccines, and adoptive
cell therapies have been developed (Gao et al., 2013; Zikich
et al., 2013). Recent remarkable advances in immuno-
therapy have provided immune checkpoint inhibitors,
which showed impressive clinical beneﬁts, as treatment
options for patients with metastatic melanoma (Pardoll,
2012; Robert et al., 2015). Although these immunotherapies
have generated durable responses, strategies to improve
response rate are still urgently required (Zikich et al., 2013;
Azijli et al., 2014).
IFN-γ, a cytokine produced by immune cells, has a crucial
role in cancer immune surveillance, promoting anti-tumor
responses (Dunn et al., 2006). IFN-γ also has a direct anti-
tumor effect on tumor cells, including melanoma (Brown
et al., 1987; Garbe et al., 1990; Gollob et al., 2005). On the
other hand, several reports have suggested that IFN-γ may
also have pro-tumorigenic effects in solid tumors under
certain circumstances (Taniguchi et al., 1987; Garbe et al.,
1990; Porter et al., 2001). A recent study in an ultraviolet
B–irradiated mouse skin cancer model demonstrated that
IFN-γ produced by macrophages promotes melanoma growth
by inhibiting apoptosis (Zaidi et al., 2011). In fact, a South-
west Oncology Group–randomized clinical trial showed that
IFN-γ had an adverse effect on melanoma relapse and
mortality rates (Meyskens et al., 1995). However, the
molecular mechanisms of IFN-γ-mediated pro-tumor effects
are not yet fully understood. Thus, elucidating the key
signaling pathways related to melanoma cell survival, which
are implicated in pro-tumor IFN-γ function, may provide new
insight into potential therapeutic targets and strategies.
CD74, also known as major histocompatibility complex
class II–associated invariant chain, is a type II transmembrane
glycoprotein and has been reported to be upregulated by IFN-
γ (Cao et al., 2000). Its role has been studied mainly in the
immune system. Although most newly synthesized CD74
protein functions as a chaperone of the major histocompa-
tibility complex class II Dα and Dβ chains (Roche et al.,
1991), a small proportion of CD74 is found on the cell surface
independent of the major histocompatibility complex class II
complex (Wraight et al., 1990; Henne et al., 1995). Cell
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surface CD74 has been identiﬁed as the high-afﬁnity receptor
for the cytokine macrophage migration inhibitory factor (MIF),
the binding of which induces signal transduction, including
activation of ERK and PI3K/AKT signaling (Shi et al., 2006;
Starlets et al., 2006). Moreover, CD74 contributes to the
regulation of several pro-tumorigenic molecules, such as IL-8
and anti-apoptotic factor BCL-2 (Beswick et al., 2005; Binsky
et al., 2007; Gore et al., 2008). Although one study reported
CD74 expression in melanoma (Weeraratna et al., 2004), the
role of CD74 in melanoma remains unclear.
In the current study, we tested our hypothesis that IFN-γ
promotes melanoma cell survival by regulating CD74–MIF
signaling. We found that IFN-γ enhances the expression of
CD74, which interacts with MIF and thereby activates
AKT signaling, as well as other pro-tumorigenic molecules,
suggesting that targeting the CD74–MIF interaction, especially
under IFN-γ-stimulatory conditions, would be an effective
therapeutic approach for melanoma.
RESULTS
IFN-γ upregulated phosphorylation of AKT Ser473
To assess the effect of IFN-γ on the major growth and survival
signaling molecules in melanoma cells, we used a reverse-
phase protein array. Cells of ﬁve melanoma lines were treated
with 0, 100, or 500 IUml−1 IFN-γ for 48 hours. Treatment
with IFN-γ markedly upregulated the phosphorylation of
AKT Ser473 in all cell lines tested (Figure 1a and Supple-
mentary Figure S1 online). Upregulated phosphorylation of
AKT Ser473 by IFN-γ stimulation was conﬁrmed with western
blot analysis (Figure 1b). These results suggest that IFN-γ
stimulation activates the AKT signaling pathways in human
melanoma cells.
Human melanoma expressed CD74
To explore which molecules functionally mediate the effect of
IFN-γ, we ﬁrst proﬁled the expression of inﬂammation-related
genes in A375 melanoma cells and normal human epidermal
melanocytes. Our PCR array result showed that 10 genes,
CD70, IL-1β, MGLL, SERPINA3, MDK, IL13RA2, CD74,
VEGFA, CXCL1, and IL-8, were increased 50-fold or more in
A375 cells compared with normal human epidermal mela-
nocytes (Supplementary Figure S2a online). On the basis of an
earlier report that CD74 expression is upregulated by IFN-γ
(Cao et al., 2000), our interests focused on CD74 among
these genes. The mRNA and protein expression of CD74 were
veriﬁed in various melanoma cell lines (Figure 2a and
Supplementary Figure S2b online). To determine whether
CD74 is expressed in melanoma tissues, we next performed
immunohistochemical staining for CD74 on a melanoma
progression tissue microarray containing tissue cores from
benign nevi, primary cutaneous melanomas, melanoma
metastases to lymph nodes, and melanoma metastases to
visceral organs (Nazarian et al., 2010). CD74 protein was
expressed (percentage score 1–3) in 33.3% of benign nevi,
94.3% of primary melanomas, and 95.9% of metastatic
melanomas. The CD74 staining intensity in primary and
metastatic melanomas was also signiﬁcantly higher than that
in nevi (Po0.0001, Figure 2b and c). These results suggest
that melanoma cells express CD74, and that expression of
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Figure 1. IFN-γ upregulates AKT Ser473 phosphorylation. Five melanoma cell lines were treated with 0, 100, or 500 IUml−1 IFN-γ for 48 hours and then
analyzed for protein expression and phosphorylation. (a) Heat map of reverse-phase protein array (RPPA) analysis. The top ﬁve upregulated and top ﬁve
downregulated proteins by IFN-γ were selected from 171 proteins and phosphorylation of key signaling molecules. Red, high expression; green, low expression.
(b) Western blot analysis. Numbers above each band indicate the relative expression level of phosphorylated AKT Ser473 (pAKT) to total AKT (AKT), calculated by
subtracting the intensity of the background before dividing the band pixel density of the target protein by the band pixel density of loading controls.
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CD74 is associated with the progression from melanocytes
and benign nevi to clinically evident melanoma.
IFN-γ stimulation increased transcription and cell surface
expression of CD74
On the basis of the above results, we hypothesized that CD74
is one of the molecules implicated in the pro-tumor function
of IFN-γ in melanoma cells. To ascertain whether IFN-γ
stimulation augments the expression of CD74 in melanoma
cells, cells treated with IFN-γ for 48 hours were assessed for
mRNA and protein expressions. IFN-γ stimulation transcrip-
tionally upregulated the expression of CD74 in all cell lines
tested (Figure 3a and Supplementary Figure S3a and b online).
Cell surface CD74 has been reported to have a role as a
signaling molecule (Starlets et al., 2006). We therefore
evaluated the presence of CD74 on the cell surface using
ﬂow cytometry and immunoﬂuorescence confocal micro-
scopic analysis. We observed modest constitutive CD74
expression on A375, SB2, WM35, and WM793 cells;
however, MeWo cells had no detectable surface expression
without IFN-γ treatment. IFN-γ increased cell surface
expression of CD74 in all cell lines examined (Figure 3b
and c, and Supplementary Figure S3c online). These results
conﬁrm that IFN-γ upregulates not only the total but also the
cell surface expression of CD74 in melanoma cells.
Expression of CD74 in melanoma tissues correlated with plasma
IFN-γ levels
Our in vitro results indicated that IFN-γ, which is available in
the tumor microenvironment, can induce cell surface CD74
expression in melanoma cells. We next analyzed the
correlation between plasma IFN-γ levels and CD74 immuno-
histochemical staining intensity in tumors from 55 melanoma
patients. Patients with high CD74 staining intensities (score 2
or 3) in tumor cells had signiﬁcantly higher plasma IFN-γ
levels than patients with low CD74 staining intensity (score 0
or 1) (Figure 3d and e). Our analysis suggests that the
expression of CD74 in tumor cells is associated with IFN-γ
levels in patients with melanoma.
Autocrine MIF-CD74 signaling regulated phosphorylation of
AKT Ser473 and expression of BCL-2, IL-6, and IL-8
Cell surface CD74 is a receptor of MIF that is a cytokine
produced by a variety of cell types, including melanoma cells
(Oliveira et al., 2014). We conﬁrmed MIF expression in all
cell lines tested (Supplementary Figure S4a and b online) and
MIF was secreted into the culture supernatant (Supplementary
Figure S5b online). Hence, we postulated that autocrine MIF
cell surface CD74 signaling has a certain role in melanoma
cells. To identify the function of the CD74–MIF interaction,
we employed (S,R)-3-(4-hydroxyphenyl)-4,5-dihydro-5-isoxa-
zole acetic acid (ISO-1), which inhibits MIF binding to CD74
(Leng et al., 2011). Treatment with ISO-1 decreased the
phosphorylation of AKT Ser473 in A375 and SB2 cells, which
constitutively have modest CD74 on their cell surfaces
(Figure 4a). As the PI3K/AKT pathway is a key signaling
pathway in cell survival, we also analyzed the expression of
the anti-apoptotic protein BCL-2. mRNA and protein expres-
sions of BCL-2 were suppressed by ISO-1 in A375, SB2,
WM35, and WM793 cells (Figure 4b and c, and Supple-
mentary Figure S5a online). As CD74 has been reported to
be involved in IL-6 and IL-8 production, we next examined
IL-6 and IL-8 expression. Treatment with ISO-1 signiﬁcantly
reduced IL-6 and IL-8 mRNA expression in four melanoma
cell lines that have cell surface CD74 (Figure 4d and e).
Analysis of culture supernatants using an antibody-based
cytokine and chemokine array showed that treatment with
ISO-1 suppressed IL-8 secretion in A375, SB2, and WM793
cells, and suppressed IL-6 secretion in WM793 cells (Supple-
mentary Figure S5b online). Interestingly, ISO-1 had no effect
on AKT phosphorylation or BCL-2, IL-6, and IL-8 expression
in cell surface CD74-negative MeWo cells. Furthermore,
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Figure 2. CD74 expression in melanoma cell lines and tissues. (a) Five
melanoma cell lines were analyzed by western blot analysis for CD74
expression. (b) Representative immunohistochemical staining intensities: score
0 (negative), 1 (weak), 2 (medium), and 3 (strong). Bar=100 μm. (c) Tissue
microarray (TMA) analysis for CD74 expression during melanoma progression.
CD74 staining was scored for the percentage (upper) and intensity (lower) of
positive tumor cells. n indicates the number of tissue cores in each group. LN,
lymph node. Both percentage and intensity score of each melanoma group
were signiﬁcantly higher compared with those for the nevus group
(Po0.0001).
K Tanese et al.
CD74 and IFN-γ in Melanoma Cell Survival
www.jidonline.org 2777
similar downregulation of BCL-2, IL-6, and IL-8 was observed
in CD74 knocked down cells (Figure 4f and Supplementary
Figure S5c online). These results suggest that MIF secreted
from melanoma cells binds to cell surface CD74 in an
autocrine manner and has a role in melanoma cell survival by
regulating the phosphorylation of AKT Ser473 and expression
of BCL-2, IL-6, and IL-8.
IFN-γ stimulation augmented CD74–MIF signaling
On the basis of our ﬁnding that IFN-γ upregulates cell surface
expression of CD74, we hypothesized that autocrine MIF–
CD74 signaling would mediate melanoma cell survival under
IFN-γ stimulation. Increased phosphorylation of AKT Ser473
by IFN-γ stimulation was suppressed by ISO-1 in a dose-
dependent manner in all cell lines tested (Figure 5a). In further
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Figure 3. CD74 expression is upregulated by IFN-γ and correlates with plasma IFN-γ levels. (a, b and c) Melanoma cell lines were treated with 0, 100, or
500 IUml− 1 IFN-γ for 48 hours and then assessed for CD74 expression. (a) Western blot analysis for total CD74 protein. Numbers above each band indicate
relative CD74 expression levels. (b) Flow cytometric analysis for cell surface CD74. Histogram: black, isotype control; red, untreated cells stained with
FITC-CD74 antibody; green, 100 IUml−1 IFN-γ-treated cells with FITC-CD74 antibody; blue, 500 IUml−1 IFN-γ-treated cells with FITC-CD74 antibody.
(c) Immunoﬂuorescence confocal microscopic analysis of cell surface CD74. Green (Alexa-488), CD74. Blue (DAPI (4',6-diamidino-2-phenylindole)), nucleus.
A375 and SB2 cells showed slight expression under normal conditions (arrows). Bar=30 μm. (d) Representative images of weak (left panels, score 1),
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Error bars, s.d. **Po0.01 and ***Po0.001.
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analysis of the cell surface CD74-negative MeWo cells, ISO-1
suppressed BCL-2 expression upregulation by IFN-γ (Figure
5b and c). In addition, IFN-γ stimulation markedly increased
IL-6 and IL-8 expression and secretion, which were strikingly
decreased by ISO-1 treatment (Figure 5d and e). Interestingly,
neither treatment with IFN-γ nor treatment with ISO-1 affected
the expression of MIF (Figure 5e). Taken together, these results
demonstrated that IFN-γ-induced cell surface expression of
CD74 promotes the activation of AKT signaling, expression of
BCL-2, and secretion of IL-6 and IL-8 through autocrine MIF–
CD74 signaling in melanoma cells.
ISO-1 suppressed tumor growth in the presence of IFN-γ in a
xenograft mouse model
To evaluate the function of the CD74–MIF interaction in vivo,
we used a xenograft mouse model. Cell surface CD74-
negative MeWo cells were injected into the ﬂank of SCID
Beige mice and then the mice were treated with ISO-1 by
daily intraperitoneal injection. As IFN-γ is species speciﬁc and
its production could be insufﬁcient in immune-deﬁcient mice,
IFN-γ was administered with or without ISO-1 to induce
CD74 expression in MeWo cells (Supplementary Figure S6
online). Although no signiﬁcant difference in tumor growth
between untreated controls and mice treated with IFN-γ alone
or ISO-1 alone was observed, ISO-1 treatment signiﬁcantly
suppressed tumor growth in the presence of IFN-γ compared
with untreated control or IFN-γ alone (Figure 6a). Tumor
weights of mice treated with IFN-γ and ISO-1 on day 21 were
signiﬁcantly lower compared with those of untreated control
mice (Figure 6b). We also observed elevated CD74 expres-
sion in tumors of IFN-γ-administered mice and MIF was
expressed in MeWo xenografts (Figure 6d). These results
suggest that inhibition of CD74–MIF interaction represses
tumor growth under IFN-γ-stimulatory conditions.
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Figure 4. Autocrine MIF–CD74 interaction regulates AKT Ser473 phosphorylation and BCL-2, IL-6, and IL-8 expression. (a and b) Cells were treated with
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DISCUSSION
In this study, we found that the cell surface CD74 responding
to IFN-γ enhances activation of AKT signaling and upregula-
tion of pro-tumorigenic molecules by binding to MIF, thereby
resulting in melanoma cell survival.
Unlike type I IFNs (IFN-α and IFN-β), which are approved
for the use in adjuvant therapies for melanoma, IFN-γ (the
only known type II IFN) has been reported to be both anti-
tumorigenic and pro-tumorigenic (Zaidi and Merlino, 2011).
Regarding the anti-tumorigenic properties of IFN-γ, treatment
with high concentrations (600–1,200 IUml− 1) of recombi-
nant IFN-γ resulted in 50% growth inhibition in some human
melanoma cell lines (Garbe et al., 1990). In contrast, our
previous study showed that treatment with 1,000 IUml−1
IFN-γ for 24 hours did not suppress the viability of A375 or
MeWo cells (Ekmekcioglu et al., 2008). In addition, IFN-γ
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enhanced lung colonization of intravenously inoculated
B16 melanoma cells (Taniguchi et al., 1987). Although the
mechanisms underlying pro-tumorigenic IFN-γ have recently
been actively investigated in terms of immunosuppressive
pathways (Zaidi and Merlino, 2011; Spranger et al., 2013),
the molecular mechanisms by which IFN-γ becomes
pro-tumorigenic in tumor cells remain poorly understood.
We now speculate that upregulation of cell surface CD74 has
a certain role in this process by promoting the survival of
melanoma cells. Upregulation of cell surface CD74 expres-
sion by IFN-γ stimulation has been reported in several cancer
cell lines, including one melanoma cell line (Ong et al., 1999;
Beswick et al., 2005). In this study, we demonstrate that IFN-γ
upregulated both transcription and cell surface expression of
CD74 in all ﬁve melanoma cell lines tested. Moreover, tumor
CD74 expression had a positive association with plasma
IFN-γ levels in patients with melanoma, suggesting that
increased CD74 expression on melanoma cells reﬂects
stimulation by IFN-γ in the tumor microenvironment.
Although CD74 expression and overexpression of MIF
(a ligand of cell surface CD74) in melanoma have been
reported (Weeraratna et al., 2004; Oliveira et al., 2014), the
functional roles of CD74 and the CD74–MIF interaction in
melanoma have not been analyzed to date. In our study, all
examined melanoma cell lines expressed MIF and modest
cell surface CD74 expression was detected in four of ﬁve
cell lines. These results provide circumstantial evidence of
autocrine MIF–CD74 signaling. Indeed, inhibition of MIF
binding to CD74 using ISO-1 suppressed the phosphorylation
of AKT Ser473 as well as the expression of BCL-2, IL-6, and
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Figure 6. MIF–CD74 inhibition suppresses tumor growth under IFN-γ-stimulatory conditions in a xenograft melanoma model. Cell surface CD74-negative
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IL-8 in cell surface CD74-positive cell lines. Similarly,
downregulation of BCL-2, IL-6, and IL-8 by CD74 knockdown
was observed, indicating the importance of CD74 in this
context. We also attempted knockdown of MIF; however,
there was no signiﬁcant difference in BCL-2, IL-6, and IL-8
expression, perhaps because melanoma cells could secrete
enough MIF to bind CD74 on the cell membrane even though
small interfering RNA efﬁciently reduced mRNA expression of
MIF (Supplementary Figure S4c and d online). In melanoma,
BCL-2 contributes to apoptosis resistance and chemotherapy
resistance (Bedikian et al., 2006), and IL-6 and IL-8 are
associated with invasiveness and metastatic potential (Bar-Eli,
1999; Kushiro et al., 2012). In addition, secretion of both IL-6
and IL-8 from tumor cells has been reported to enrich the
Foxp3+ CD4–regulatory T-cell subset among T cells migrating
toward melanoma, thereby creating an immunosuppressive
microenvironment (Eikawa et al., 2010). Taken together, these
ﬁndings suggest that CD74–MIF autocrine signaling is active
in melanoma and may have roles in tumor cell survival,
invasion, and immunosuppression.
We also demonstrated that the cell surface CD74–MIF
signaling is augmented in response to IFN-γ. Blockade of the
CD74–MIF interaction by ISO-1 reduced AKT phosphoryla-
tion, promoting cell survival. Importantly, these ﬁndings were
observed regardless of the BRAF or NRAS mutation status,
implying that the augmentation of CD74–MIF signaling by
IFN-γ is a universal phenomenon in melanoma cells. Despite
high rates of clinical response, resistance to BRAF inhibitors
emerges in most patients with metastatic melanoma (Salama
and Flaherty, 2013). Given that the AKT pathway is one of the
mediators of BRAF inhibitor resistance (Perna et al., 2015), the
MIF–CD74 axis in melanoma cells may maintain AKT phos-
phorylation and interrupt the beneﬁts of BRAF inhibitors,
perhaps by IFN-γ from the melanoma microenvironment.
In our mouse study using MeWo cells, which have no cell
surface CD74 without IFN-γ stimulation, inhibition of CD74–
MIF interaction signiﬁcantly suppressed tumor growth in the
presence of IFN-γ. This result suggested that CD74–MIF
signaling promotes melanoma cell survival in response to
IFN-γ in vivo. Although the current study was limited to
immune-deﬁcient conditions, our ﬁndings provide evidence
that CD74–MIF inhibition may have a therapeutic potential
for melanoma when combined with immune-stimulatory
therapies.
In conclusion, IFN-γ enhances the expression of CD74,
which then is able to interact with an autocrine or
extracellular MIF, or both, and thereby activates the PI3K/
AKT pathway in melanoma, promoting tumor survival.
Targeting the CD74–MIF interaction, especially under IFN-γ-
stimulatory conditions, would be an effective therapeutic
approach for melanoma.
MATERIALS AND METHODS
Patient samples
This research project was approved by both the Surveillance
Committee for Human Subjects Research and the Vice President
for Research at The University of Texas MD Anderson Cancer Center.
Fifty-ﬁve melanoma patients presenting with clinically localized
disease in the Melanoma Surgery Clinic at MD Anderson between
September 2004 and April 2007 were included, and written informed
consent was obtained from all patients according to the Declaration
of Helsinki Principles. All patients underwent standard deﬁnitive
surgery for their primary tumors. Plasma samples (obtained from each
patient before wide local tumor excision and sentinel lymph node
biopsy) were stored at − 80 °C until analysis.
Cell lines and reagents
The human melanoma cell lines A375 and MeWo were obtained
from the American Type Culture Collection. WM35 and WM793
cells and SB2 cells were provided by Dr Robert Kerbel (Sunnybrook
Health Sciences Centre, Toronto, Ontario, Canada) and Dr Jeffrey
Gershenwald (MD Anderson), respectively. All melanoma cells were
grown under conditions as described elsewhere (Ekmekcioglu et al.,
2008). Normal human epidermal melanocytes were obtained from
Lonza (Walkersville, MD) and cultured in Melanocyte Cell Basal
Medium-4 supplemented with the MGM-4 Bullet Kit (Lonza). All
cells were grown at 37 °C in a 5% CO2 atmosphere and cultured to
50–60% conﬂuence a day before the start of the experiment. The cell
lines were validated via STR DNA ﬁngerprinting using the AmpF/STR
identiﬁer kit according to the manufacturer’s instructions (Applied
Biosystems, Carlsbad, CA).
Cells were treated with the MIF inhibitor ISO-1 (Calbiochem, La
Jolla, CA) and human recombinant IFN-γ protein (eBioscience, San
Diego, CA). The primers corresponding to short hairpin RNA
targeting CD74 sequences were synthesized (Sigma-Aldrich, St
Louis, MO), annealed, and inserted between BamHI and EcoRI
restriction sites in the multiple cloning cassette of the pSIREN-Shuttle
vector (Clontech, Mountain View, CA). Sequences used are listed in
Supplementary Table S1 online. The U6 promoter–short hairpin RNA
cassettes were then excised and recloned to KpnI and ApaI sites
of the pEPI-1 vector containing green ﬂuorescent protein expression
marker, kindly provided by Dr A.C. Jenke (HELIOS Children’s
Hospital, Wuppertal, Germany). The construct was transfected into
melanoma cells using Fugene6 (Promega, Madison, WI) and
transfected cells were treated with puromycin (Invitrogen, Carlsbad,
CA) for 2 weeks. Puromycin-resistant colonies were collected by
trypsinization and used without cloning.
Reverse-phase protein array
The reverse-phase protein array method used was described
elsewhere (Tibes et al., 2006). Brieﬂy, cells were lysed in lysis
buffer, and then SDS/2-ME buffer was added and the solution
incubated for 5 minutes at 95 °C. The lysate material was printed
onto nitrocellulose-coated glass slides using the GeneTac arrayer
(Genomic Solutions, Ann Arbor, MI). Slides were blocked for
endogenous peroxidase, avidin, and biotin activity, and primary
antibody was added. Next, a biotinylated secondary antibody and
a streptavidin–biotin complex were added. The DAKO signal
ampliﬁcation system (Copenhagen, Denmark) was used to detect
and amplify antibody-binding intensity. The intensity of each spot
was calculated using MicroVigene software (VigeneTech, North
Billerica, MA).
Antibodies and western blotting
Goat polyclonal anti-human actin (I-19; Santa Cruz, Carlsbad, CA),
mouse monoclonal anti-human CD74 (PIN.1; Novus Biologicals,
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Littleton, CO), mouse monoclonal anti-human BCL-2 (124; GeneTex,
San Antonio, TX), goat polyclonal anti-human MIF (R&D Systems,
Minneapolis, MN), and rabbit monoclonal anti-human total
AKT, phosphorylated AKT Ser473 (Cell Signaling Technology,
Danvers, MA) antibodies were used as primary antibodies;
horseradish peroxidase–labeled anti-mouse, anti-rabbit, and anti-
goat antibodies (1:1,000; DAKO) were used as secondary anti-
bodies. Amersham ECL western blot detection reagent (GE Health-
care, Piscataway, NJ) was used to detect protein expression.
Protein expression bands were captured on Kodak BioMax ﬁlm
and recorded using a computer scanner. Band pixel density
was quantiﬁed with Photoshop CS5.1 software (Adobe, San
Jose, CA).
Melanoma tissue microarray and immunohistochemistry
A melanocytic tumor progression tissue microarray composed of 480
cores from clinically stratiﬁed melanocytic samples obtained from
170 patients served as a template for investigating IL-1 in human
melanocytic tumors (Nazarian et al., 2010; Qin et al., 2011). The
immunohistochemistry protocol used was described previously
(Ekmekcioglu et al., 2006). Mouse monoclonal anti-human CD74
(PIN.1) was used as the primary antibody. Immunolabeling was
scored separately for two variables: percentage of melanoma cells
with positive staining (o5%, 0; 5–25%, 1; 26–75%, 2; 475%, 3)
and overall intensity of the immunoreactivity in positive cells
(negative, 0; weak, 1; medium, 2; strong, 3). Specimens were
considered to be positive if either the percentage or the intensity
score was 1 to 3. All specimens were manually scored by two
researchers (SE and KT) independently, without prior knowledge of
other clinical information.
Measurement of plasma IFN-γ levels
Plasma IFN-γ levels were determined using a commercially available
ELISA assay kit (BioSource International, Camarillo, CA) according to
the manufacturer’s recommendations.
Extraction of RNA and quantitative real-time PCR
Total cellular RNA was isolated using the RNeasy mini kit
(Qiagen, Valencia, CA). RNA samples were treated with TURBO
DNase (Ambion, Foster City, CA) to remove genomic DNA and
converted to ﬁrst-strand cDNA using the GeneAmp RNAPCR kit
(Applied Biosystems). Quantitative real-time PCR analysis was
performed using a Mastercycler ep realplex real-time PCR system
(Eppendorf, Westbury, NY) with RT2 SYBR Green qPCR
Master Mix (Qiagen). Primer sequences used are listed in Supple-
mentary Table S1 online. Human GAPDH was used as an internal
reference. Fold-induction values were calculated using the 2−ΔΔCt
method.
Focused protein array
Secreted proteins in each culture supernatant were measured using a
human cytokine array panel A kit (Proteome Proﬁler; R&D Systems).
Protein expression dots were scanned using a computer scanner and
dot pixel density was quantiﬁed using Photoshop CS5.1 software.
Relative dot density was calculated by subtracting the intensity of the
background before dividing the average dot pixel density of duplicate
target proteins by the average dot pixel density of three positive
controls.
CD74 cell surface expression analysis
Melanoma cells were cultured with or without IFN-γ (100 IUml−1)
for 48 hours. Cells were subsequently treated with chondroitinase
ABC (0.1 Uml− 1; Sigma-Aldrich) for 4 hours at 37 °C, washed with
ice-cold phosphate-buffered saline, detached by gentle pipetting,
and subsequently ﬁxed with 1% paraformaldehyde in phosphate-
buffered saline. Cells were stained with FITC-conjugated mouse
monoclonal anti-human CD74 antibody (M-B741) or its isotype
control antibody (IgG2a, κ; BD Biosciences, San Jose, CA) and
analyzed using a FACSCalibur ﬂow cytometer (BD Biosciences). For
immunoﬂuorescence staining, cells were incubated with mouse
anti-CD74 antibody (M-B741) or isotype control antibody
(BD Biosciences) for 1 hour and then incubated with Alexa Fluor
488–labeled goat anti-mouse IgG antibody (Life Technologies,
Carlsbad, CA) for 1 hour. Slides were photographed using a confocal
ﬂuorescence microscope (FV1000; Olympus, Melville, NY).
Mouse xenograft model study
The mouse study was conducted at TD2 (Scottsdale, AZ). MeWo
cells (1.5×107) were subcutaneously inoculated into the ﬂanks of
SCID Beige mice. Six days after cell injection, mice were randomly
assigned to receive intraperitoneal treatment with ISO-1 (500 μg
per day) and/or IFN-γ (1,000 IU per day) daily for 21 days. Tumor
growth was monitored for 21 days. Tumor weights were recorded
when mice were euthanized on day 21 (Supplementary Figure S6
online).
Statistical analysis
All statistical analyses were performed using SAS software (SAS
Institute, Cary, NC) and S-PLUS software (TIBCO Software) with
signiﬁcance determined using Student’s t-test or the Mann–Whitney
U-test. Po0.05 was considered statistically signiﬁcant.
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